Bolt Biotherapeutics, Inc. (BOLT) vs Traws Pharma, Inc. (TRAW)

Bolt Biotherapeutics, Inc. and Traws Pharma, Inc. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and Traws Pharma, Inc. are of similar size ($7.3M and $6.9M). Traws Pharma, Inc. grew revenue faster over the last twelve months: 1,159.3% against 12.8%. Traws Pharma, Inc. has the higher net margin (0.00% vs −611.5%) and the higher return on invested capital (0.00% vs −143.8%). Across the 17 metrics below, Traws Pharma, Inc. leads on 10 and Bolt Biotherapeutics, Inc. on 7.

Valuation

Metric BOLT TRAW Biotechnology median
P/E n/m n/m 7.88
P/S 1.32 3.12 11.47
P/B 0.49 5.25 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.48 1.36 10.73
Earnings yield (447.96%) (314.29%) (28.84%)
Free cash flow yield (496.60%) (189.82%) (23.03%)

Profitability

Metric BOLT TRAW Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (654.53%) 0.00% 0.00%
Net margin (611.47%) 0.00% 0.00%
Free cash flow margin (655.72%) 0.00% 0.00%
Return on equity (111.65%) (319.42%) (57.72%)
Return on assets (49.62%) (117.35%) (49.22%)
Return on invested capital (143.75%) 0.00% 0.00%

Growth

Metric BOLT TRAW Biotechnology median
Revenue growth (TTM) 12.79% 1,159.29% 5.64%
EPS growth (last fiscal year) 45.91% 100.76% —
Revenue growth, 5-year CAGR 101.61% 64.59% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BOLT TRAW Biotechnology median
Debt to equity 1.47 0.00 0.00
Current ratio 2.61 0.93 4.73
Net debt to EBITDA 0.21 0.21 0.96

Dividend

Metric BOLT TRAW Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BOLT TRAW Biotechnology median
Market cap 6.92m 7.26m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack